ArticleCancer prevention research (Philadelphia, Pa.)2015
MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas.
Article in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Where do we stand with screening for colorectal cancer and advanced adenoma based on serum protein biomarkers? A systematic review.Molecular oncology · 2024Pooled it
- Signals from the Adipose Microenvironment and the Obesity-Cancer Link-A Systematic Review.Cancer prevention research (Philadelphia, Pa.) · 2017Pooled it
- Construction of a prognostic model using lactylation-related genes for predicting the prognosis of glioma patients.Medicine · 2026Article
- Proteomic remodeling during tumor cell-induced platelet aggregation unveils metastatic drivers in colorectal cancer.Cancer cell international · 2026Article
- Yes-associated protein plays oncogenic roles in human sporadic colorectal adenomas.Carcinogenesis · 2025Article
- The non-invasive diagnosis of colorectal cancer via a SOX9-based gene panel.Clinical and experimental medicine · 2023Article
- MiR-526b-3p Inhibits the Resistance of Glioma Cells to Adriamycin by Targeting MAPRE1.Journal of oncology · 2022Article
- Identification of potential biomarkers for diagnosis of hepatocellular carcinoma.Experimental and therapeutic medicine · 2022Article
- Article
- A genome-wide study of the relationship between chromosomal abnormalities and gene expression in colorectal tumors.Genes, chromosomes & cancer · 2021Article
- Article
- circSETD3 regulates MAPRE1 through miR-615-5p and miR-1538 sponges to promote migration and invasion in nasopharyngeal carcinoma.Oncogene · 2021Article
- Non-invasive Potential Circulating mRNA Markers for Colorectal Adenoma Using Targeted Sequencing.Scientific reports · 2019Article
- Single-Gene Deletions Contributing to Loss of Heterozygosity inG3 (Bethesda, Md.) · 2019Article
- A plasma protein derived TGFβ signature is a prognostic indicator in triple negative breast cancer.NPJ precision oncology · 2019Article
- Blood-Based Protein Signatures for Early Detection of Colorectal Cancer: A Systematic Review.Clinical and translational gastroenterology · 2017Article
- Cell Line Secretome and Tumor Tissue Proteome Markers for Early Detection of Colorectal Cancer: A Systematic Review.Cancers · 2017Review
- Estimation of smooth ROC curves for biomarkers with limits of detection.Statistics in medicine · 2017Article
- Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.Oncotarget · 2016Article
- Optimizing mouse models for precision cancer prevention.Nature reviews. Cancer · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 2 institutions in 1 country.
Funding
Abstract
Blood-based biomarkers for early detection of colorectal cancer could complement current approaches to colorectal cancer screening. We previously identified the APC-binding protein MAPRE1 as a potential colorectal cancer biomarker. Here, we undertook a case-control validation study to determine the performance of MAPRE1 in detecting early colorectal cancer and colon adenoma and to assess the potential relevance of additional biomarker candidates. We analyzed plasma samples from 60 patients with adenomas, 30 with early colorectal cancer, 30 with advanced colorectal cancer, and 60 healthy controls. MAPRE1 and a set of 21 proteins with potential biomarker utility were assayed using high-density antibody arrays, and carcinoembryonic antigen (CEA) was assayed using ELISA. The biologic significance of the candidate biomarkers was also assessed in colorectal cancer mouse models. Plasma MAPRE1 levels were significantly elevated in both patients with adenomas and patients with colorectal cancer compared with controls (P < 0.0001). MAPRE1 and CEA together yielded an area under the curve of 0.793 and a sensitivity of 0.400 at 95% specificity for differentiating early colorectal cancer from controls. Three other biomarkers (AK1, CLIC1, and SOD1) were significantly increased in both adenoma and early colorectal cancer patient plasma samples and in plasma from colorectal cancer mouse models at preclinical stages compared with controls. The combination of MAPRE1, CEA, and AK1 yielded sensitivities of 0.483 and 0.533 at 90% specificity and sensitivities of 0.350 and 0.467 at 95% specificity for differentiating adenoma and early colorectal cancer, respectively, from healthy controls. These findings suggest that MAPRE1 can contribute to the detection of early-stage colorectal cancer and adenomas together with other biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.